Holywood Community Network is inviting everyone to come along to the mural unveiling event, celebrating their efforts and ...

The 456-subject trial named ARTISTRY-7 was designed to evaluate Mural’s (NASDAQ:MURA) antitumor agent with Merck’s (MRK) anti-PD-1 therapy, Keytruda, against the investigator’s choice ...

Mural Oncology plc (MURA), a pharmaceutical ... which indicated that the drug, in combination with Merck (NSE:PROR)’s anti-PD-1 therapy KEYTRUDA® (pembrolizumab), did not show a statistically ...

Mural Oncology plc (MURA), a pharmaceutical company focused on developing ... This decision follows the results of a pre-specified interim analysis by an independent data monitoring committee, which ...

Mural Oncology said that it won't continue developing its ovarian cancer drug candidate Nemvaleukin ... alfa in combination with Merck's anti-PD-1 therapy, Keytruda, didn't achieve a statistically ...